Compass Therapeutics (CMPX) vs Fate Therapeutics (FATE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Compass Therapeutics (CMPX) over the past year, losing 10.8% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -98.3% for FATE. Compass Therapeutics is the larger company by market cap ($123.9 million vs $111.8 million), about 1.1 times the size, while Fate Therapeutics is growing revenue faster (-51.2% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | FATE |
|---|---|---|
| Share price | $0.6882 | $0.919 |
| Market cap | $123.94M | $111.82M |
| 1-day change | +1.43% | -9.01% |
| YTD return | -87.18% | -6.22% |
| 1-year return | -85.87% | -10.78% |
| 5-year return | -78.63% | -98.25% |
| EPS (TTM) | $-0.46 | $-1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $6.65M |
| Revenue growth (YoY) | -100.00% | -51.24% |
| Net income (latest FY) | $-66.49M | $-136.31M |
| Operating margin | — | -2222.45% |
| Net margin | — | -2051.08% |
| 52-week high | $6.88 | $3.23 |
| 52-week low | $0.57 | $0.90 |
| Distance from 52-week high | -90.00% | -71.55% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +664.31% | +522.42% |
| Average volume | 3.88M | 1.53M |
| Shares outstanding | 180.09M | 121.67M |
| Employees | 39 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed CMPX by 75.1 percentage points over the past year.
- Fate Therapeutics grew revenue faster in its latest fiscal year (-51.24% vs -100.00%).
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
CMPX vs FATE FAQ
Which is bigger, Compass Therapeutics or Fate Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $111.82M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, CMPX or FATE?
FATE returned -10.78% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Fate Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.